CA2718289A1 - Anti-tyrp1 antibodies - Google Patents

Anti-tyrp1 antibodies Download PDF

Info

Publication number
CA2718289A1
CA2718289A1 CA2718289A CA2718289A CA2718289A1 CA 2718289 A1 CA2718289 A1 CA 2718289A1 CA 2718289 A CA2718289 A CA 2718289A CA 2718289 A CA2718289 A CA 2718289A CA 2718289 A1 CA2718289 A1 CA 2718289A1
Authority
CA
Canada
Prior art keywords
antibody
seq
antibodies
fragment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718289A
Other languages
English (en)
French (fr)
Inventor
Xiaoqiang Kang
Paul J. Balderes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2718289(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of CA2718289A1 publication Critical patent/CA2718289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2718289A 2008-03-12 2009-03-11 Anti-tyrp1 antibodies Abandoned CA2718289A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6919908P 2008-03-12 2008-03-12
US61/069,199 2008-03-12
PCT/US2009/036739 WO2009114585A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Publications (1)

Publication Number Publication Date
CA2718289A1 true CA2718289A1 (en) 2009-09-17

Family

ID=40790741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718289A Abandoned CA2718289A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Country Status (19)

Country Link
US (1) US7951370B2 (enExample)
EP (1) EP2268672A1 (enExample)
JP (1) JP2011516041A (enExample)
KR (1) KR101203777B1 (enExample)
CN (1) CN101970500B (enExample)
AR (1) AR070821A1 (enExample)
AU (1) AU2009222998B2 (enExample)
BR (1) BRPI0909633A2 (enExample)
CA (1) CA2718289A1 (enExample)
CL (1) CL2009000567A1 (enExample)
EA (1) EA019517B1 (enExample)
IL (1) IL207581A0 (enExample)
MX (1) MX2010010021A (enExample)
NZ (1) NZ587305A (enExample)
PE (1) PE20091679A1 (enExample)
TW (1) TWI384997B (enExample)
UA (1) UA99339C2 (enExample)
WO (1) WO2009114585A1 (enExample)
ZA (1) ZA201006099B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101163295B1 (ko) * 2007-06-29 2012-07-05 에프. 호프만-라 로슈 아게 향상된 면역글로불린을 생산하는 중쇄 돌연변이체
JP6464436B2 (ja) 2014-02-07 2019-02-06 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 受容体共役タンパク質キナーゼ−３（ｒｉｐ３）発現促進剤を有効成分として含む抗癌補助用組成物、受容体共役タンパク質キナーゼ−３（ｒｉｐ３）の発現を促して抗癌剤感受性を増進させる抗癌補助剤のスクリーニング方法及び抗癌剤感受性のモニターリング方法
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
KR20200021074A (ko) * 2017-06-14 2020-02-27 아디셋 바이오, 인크. Hla 제한된 방식으로 hla-a2/tyrd를 결합할 수 있는 항체 및 이의 용도
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
SG11202102781UA (en) 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
JP7440509B2 (ja) 2018-11-09 2024-02-28 ベス イスラエル デアコネス メディカル センター Ｃｄｃｐ１－標的化療法
SG11202102859TA (en) 2018-12-21 2021-04-29 Hoffmann La Roche Antibodies binding to cd3
US20230049954A1 (en) * 2019-09-06 2023-02-16 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
EP4121454A1 (en) * 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
CN118284625A (zh) * 2021-11-26 2024-07-02 豪夫迈·罗氏有限公司 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
AU2024381207A1 (en) 2023-11-17 2026-05-14 Institut National de la Santé et de la Recherche Médicale Antineoplastic combinations
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798790A (en) 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
IE20000918A1 (en) 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
AU6171196A (en) * 1995-06-07 1996-12-30 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
EP1805320B1 (en) * 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies

Also Published As

Publication number Publication date
TW200944232A (en) 2009-11-01
US7951370B2 (en) 2011-05-31
PE20091679A1 (es) 2009-11-04
AU2009222998A1 (en) 2009-09-17
AU2009222998B2 (en) 2013-05-23
JP2011516041A (ja) 2011-05-26
IL207581A0 (en) 2010-12-30
WO2009114585A1 (en) 2009-09-17
CN101970500A (zh) 2011-02-09
TWI384997B (zh) 2013-02-11
AR070821A1 (es) 2010-05-05
EP2268672A1 (en) 2011-01-05
KR20100113631A (ko) 2010-10-21
ZA201006099B (en) 2012-01-25
KR101203777B1 (ko) 2012-11-21
NZ587305A (en) 2012-05-25
CL2009000567A1 (es) 2010-02-26
MX2010010021A (es) 2011-02-15
BRPI0909633A2 (pt) 2015-09-22
EA019517B1 (ru) 2014-04-30
US20090232823A1 (en) 2009-09-17
UA99339C2 (ru) 2012-08-10
CN101970500B (zh) 2013-08-14
EA201071068A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
US7951370B2 (en) Anti-TYRP1 antibodies
US8071099B2 (en) Anti-FLT3 antibodies
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
AU2007324509B2 (en) Novel antiproliferation antibodies
KR20170003912A (ko) 면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도
JP2011516041A5 (enExample)
CN114907479B (zh) 抗cd112r抗体及其用途
CN116059341A (zh) 药物组合物及用途
KR20230024323A (ko) 항-tigit 항체 및 이의 용도
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
HK40089230A (en) Pharmaceutical composition and use
HK40060091A (en) Antibodies specific for gucy2c and uses thereof
HK1176626A (en) Antibodies against csf-1r
HK1176626B (en) Antibodies against csf-1r

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150311